SLP
Simulations Plus, Inc. · Healthcare
12.46
3.92%(+0.47)
Prev. Close13.10
5.14%(+0.64)
Pre-marketLast Updated: — ET
52W L: $11.0952W H: $36.45
$12.22
CHG+0.22 (+1.83%)
H$12.71
L$11.10
VOL3.3M
SLP (1h)
Simulations Plus, Inc. · Healthcare
JPMorgan Chase and Co. boosted its stake in shares of Simulations Plus, Inc. (NASDAQ: SLP) by 154.7% during the undefined quarter, according to its most recent filing with the SEC. The firm owned 167,646 shares of the technology company's stock after purchasing an additional 101,822 shares during the period. JPMorgan Chase and Co.
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that it will report second quarter fiscal 2026 financial results after the market close on Thursday, April 9, 2026. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and.
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced strategic collaboration programs with three large pharmaceutical companies to advance artificial intelligence (AI) workflows across the drug development lifecycle. These programs apply AI within scientifically grounded modeling workflows and define how n.
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a high-impact panel discussion, “From Debate to Deployment: Responsible, Practical AI in MIDD,” to be held during the upcoming American Society for Clinical Pharmacology & Therapeutics (ASCPT) Annual Meeting on March 5, 2026 at 12:00 PM MST in Denver.
New York, New York--(Newsfile Corp. - February 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Simulations Plus securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the extension of two separate research collaborations with the U.S. Food and Drug Administration (FDA) and the National Institute of Environmental Health Sciences (NIEHS). The extended projects support ongoing federal research efforts focused on the deve.
DiBella John Anthony II
officer: Chief Revenue Officer
10,300 SH @ $9.71
2026-02-06
DiBella John Anthony II
officer: Chief Revenue Officer
10,300 SH @ $9.71
2026-02-06
WOLTOSZ WALTER S
director, 10 percent owner:
1,776 SH @ $0.00
2026-01-30
Evans Sharlene
director
1,776 SH @ $0.00
2026-01-30
WEINER DANIEL L
director
1,776 SH @ $0.00
2026-01-30
Paglia John Kenneth
director
1,776 SH @ $0.00
2026-01-30
Fiedler-Kelly Jill
officer: President, Services Solutions
8,950 SH @ $9.71
2026-01-28
Fiedler-Kelly Jill
officer: President, Services Solutions
8,950 SH @ $9.71
2026-01-28